FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy

FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy


Signage is seen outside the U.S. Food and Drug Administration headquarters in White Oak, Maryland, Aug. 29, 2020.

Andrew Kelly | Reuters

The U.S. Food and Drug Administration has warned that some Tydemy birth control pills may not be effective, several days after the manufacturer recalled two batches of the medication that were distributed in the U.S.

The FDA said the pills in question could result in unexpected pregnancy. The agency has not received any reports of adverse events related to Tydemy so far.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

The manufacturer, Lupin Pharmaceuticals, announced a voluntary recall of two batches of Tydemy on July 29. The pills in those batches were distributed in the U.S. between June 3, 2022, and May 31, 2023.

CNBC Health & Science

Read CNBC’s latest health coverage:

Lupin, in a statement last week, said it recalled the batches because pills in one batch tested low for ascorbic acid and “high for a known impurity.” The company said a significant reduction in ascorbic acid could affect the product’s effectiveness.

Lupin said it is notifying wholesalers, distributors, drug chains and supermarkets of the problem and is working to get the affected pills off store shelves. Any store, distributor or wholesaler that has the affected pills in stock should immediately stop distributing them, the company said.

The batches of Tydemy that may not be effective come from lot numbers L200183 and L201560.

Lupin advised patients to continue taking their medication and immediately consult with their doctor about an alternative form of contraception.



Source

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Health

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]

Read More
Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug
Health

Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug

Thomas Fuller | SOPA Images | Lightrocket | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer‘s newest bet on obesity is already showing promise.  The company last week said it would buy […]

Read More
Trump, Pfizer to announce agreement to lower Medicaid drug prices
Health

Trump, Pfizer to announce agreement to lower Medicaid drug prices

U.S. President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025. Nathan Howard | Reuters President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices […]

Read More